Finally, due to the lack of relevant clinical trials, we did not perform exploratory analyses of prognostic biomarkers (e.g. epigenetic profiles of methylation and concentrations of 2-HG in serum) associated with IDH inhibitors in IDH-mutated AML patients [49, 50]. This evidence concerns the gene IDH2 and acute myeloid leukemia.